Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chabner

Showing results (61-70 of 456) with videos related to

Pageof 46
Sort By:
Journal of the National Cancer Institute|December 7, 1988
In celebration of a Nobel PrizeB A Chabner
Clinical Pharmacology and Therapeutics|November 15, 2017
Considerations About the Use of Biomarkers in Cancer Clinical TrialsBruce A Chabner
Japanese Journal of Cancer Research : Gann|December 1, 1993
Multidrug resistance: mechanism and therapyB A Chabner
The Oncologist|June 1, 2004
The miracle of IressaBruce A Chabner
The Oncologist|September 30, 2008
Preserving the sacred bond: an audit must be performedBruce A Chabner
The Oncologist|June 4, 2017
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"Bruce A Chabner
Blood|October 1, 1990
Salvage therapy for diffuse large-cell lymphomaB A Chabner
The New England Journal of Medicine|March 25, 2011
Early accelerated approval for highly targeted cancer drugsBruce A Chabner
The New England Journal of Medicine|July 28, 1977
Second neoplasm--a complication of cancer chemotherapyB A Chabner
Journal of the National Cancer Institute|January 13, 2016
NCI-60 Cell Line Screening: A Radical Departure in its TimeBruce A Chabner
Pageof 46

Showing results (61-70 of 456) with videos related to

Sort By:
Pageof 46
Journal of the National Cancer Institute|December 7, 1988
In celebration of a Nobel PrizeB A Chabner
Clinical Pharmacology and Therapeutics|November 15, 2017
Considerations About the Use of Biomarkers in Cancer Clinical TrialsBruce A Chabner
Japanese Journal of Cancer Research : Gann|December 1, 1993
Multidrug resistance: mechanism and therapyB A Chabner
The Oncologist|June 1, 2004
The miracle of IressaBruce A Chabner
The Oncologist|September 30, 2008
Preserving the sacred bond: an audit must be performedBruce A Chabner
The Oncologist|June 4, 2017
Regarding "Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies"Bruce A Chabner
Blood|October 1, 1990
Salvage therapy for diffuse large-cell lymphomaB A Chabner
The New England Journal of Medicine|March 25, 2011
Early accelerated approval for highly targeted cancer drugsBruce A Chabner
The New England Journal of Medicine|July 28, 1977
Second neoplasm--a complication of cancer chemotherapyB A Chabner
Journal of the National Cancer Institute|January 13, 2016
NCI-60 Cell Line Screening: A Radical Departure in its TimeBruce A Chabner
Pageof 46